W. U. Shipley

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

R. Abrams, P. Rubin, W. Sause, 1995, Urology.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

M. Hammond, H. Sandler, M. Desilvio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03.

B. Donnelly, W. Shipley, C. Perez, 1998, The Journal of urology.

Selective bladder preservation by combination treatment of invasive bladder cancer.

W. Shipley, A. Althausen, N. Heney, 1993, The New England journal of medicine.

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.

L. True, R. Whittington, R. Byhardt, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Results of Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC - Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.

A. Zietman, J. Efstathiou, A. Jani, 2024, International journal of radiation oncology, biology, physics.